Barely Significant
← all excerpts

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.

Ann Rheum Dis · 2022 · PMC9213793 · PMID 35580976

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

did not reach statistical significanceno p-value reported
WHAT IS ALREADY KNOWN ON THIS TOPIC In the anifrolumab clinical development programme for patients with systemic lupus erythematosus (SLE), clinical efficacy outcomes in favour of anifrolumab were consistently observed across the composite endpoints BILAG-based Composite Lupus Assessment (BICLA) and SLE Responder Index (SRI(4)) in the phase 3 TULIP-2 trial and the phase 2b MUSE trial, but not in the phase 3 TULIP-1 trial, for which SRI(4) treatment differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.